SOURCE: Stem Cell Therapy International, Inc.

Stem Cell Therapy International, Inc.

February 08, 2010 12:00 ET

Histostem Participates in Successful Stem Cell Treatment for Acute Spinal Cord Injury in Dogs

TAMPA, FL--(Marketwire - February 8, 2010) - Stem Cell Therapy International, Inc. (OTCBB: SCII) announced that Histostem Ltd. of South Korea ("Histostem") has participated in a study resulting in the successful treatment of spinal cord injury in dogs through the use of Multipotent Stem Cells (MSCs) derived from Human Umbilical Cord Blood (HUCB). The study, a collaborative effort between a team of doctors from the Departments of Veterinary Surgery and Veterinary Anatomy at Konkuk University, Seoul, Korea and Dr. Hoon Han, President and Founder of Histostem, presented a method for the percutaneous transplantation of stem cells and investigated the therapeutic efficacy of transplanting stem cells to improve the recovery of the central nervous system following such acute spinal cord injury.

While previous research on spinal cord injury has typically used rats, this study used dogs which have a spinal cord structure more similar to humans. Within the test group, those dogs that received cellular transplants exhibited gradual improvement in hind limb locomotion two to three weeks after the transplant and also demonstrated reduced cyst and injury size.

Dr. Han commented, "Our research demonstrated a new, less invasive method of transplanting human umbilical cord blood derived multipotent stem cells, which avoids surgical exposure and allows the cells to be more precisely transplanted into the spinal cord. In addition to this breakthrough in the technique used to transplant stem cells, we also had success in improving the condition of the spinal cord injury among the test group. Based on the successful results of this study and because of the canine spinal cord's resemblance to a human spinal cord, we are optimistic that this technique has many potential applications in the treatment of human spinal cord injury through stem cell transplantation."

More details on the research process and results are available in the December 2009 issue of the Journal of Neurosurgery: Spine.

About Stem Cell Therapy International, Inc.

Stem Cell Therapy International, Inc. (OTCBB: SCII) is in the field of regenerative medicine. SCII (soon to be renamed AmStem Corporation) is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.

About AmStem International Inc.

Amstem International Inc. ("AmStem") is a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Its web site is under construction at

About Histostem Co. Ltd.

Histostem was founded in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has approximately 50 full-time employees and several part-time employees. Histostem's intellectual property portfolio consists of 6 patents that have been granted and 5 patents pending. To its knowledge, Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. A comprehensive list of Histostem's achievements can be found at the company's website (click on English version when entering the site).

Forward-Looking Statements

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Stem Cell Therapy International, Inc. may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contact Information

    Stem Cell Therapy International, Inc.
    (813) 283-2556
    David Stark

    Andrew Norstrud

    Investor relations:
    Jennifer Belodeau/John Nesbett
    Institutional Marketing Services (IMS)
    (203) 972-9200

    Stem Cell Therapy International, Inc.
    13406 Racetrack Road #233
    Tampa, FL 33626